Chen Qiyu, aged 49, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a co-chairman of New Frontier Health Corporation (delisted from the New York Stock Exchange in January 2022), a director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited), Sanyuan Foods (listed on the SSE) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange with stock code 300244) and a non-executive director of BabyTree (listed on the Hong Kong Stock Exchange). As at the end of the Reporting Period, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, and a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference. Mr. Chen was awarded"Asia’s Best CEO" by Corporate Governance Asia , etc.. Mr. Chen received a bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.